Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a perioperative phase 1 trial to explore the mechanism of action in recurrent low-grade glioma (IGG) and select a molecule...

Descripción completa

Detalles Bibliográficos
Autores principales: Mellinghoff, Ingo K., Lu, Min, Wen, Patrick Y., Taylor, Jennie W., Maher, Elizabeth A., Arrillaga-Romany, Isabel, Peters, Katherine B., Ellingson, Benjamin M., Rosenblum, Marc K., Chun, Saewon, Le, Kha, Tassinari, Ania, Choe, Sung, Toubouti, Youssef, Schoenfeld, Steven, Pandya, Shuchi S., Hassan, Islam, Steelman, Lori, Clarke, Jennifer L., Cloughesy, Timothy F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313524/
https://www.ncbi.nlm.nih.gov/pubmed/36823302
http://dx.doi.org/10.1038/s41591-022-02141-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313524/
https://www.ncbi.nlm.nih.gov/pubmed/36823302
http://dx.doi.org/10.1038/s41591-022-02141-2

Ejemplares similares